Endocrinology (all articles)
A review of the epidemiology, pathophysiology, and efficacy of anti-diabetic drugs used in the treatment of nonalcoholic fatty liver disease.
27 Aug, 2021 | 08:59h | UTC
Expert analysis: Ideal Aspirin Dose for Secondary Prevention in Patients with ASCVD – “A lower-dose aspirin strategy is best for most patients with ASCVD given similar effectiveness, bleeding risk, and overall better adherence”.
26 Aug, 2021 | 08:42h | UTCIdeal Aspirin Dose for Secondary Prevention in Patients With ASCVD – American College of Cardiology
New USPSTF statement recommends overweight and obese individuals should undergo screening for Prediabetes and Type 2 Diabetes at age 35 instead of 40.
25 Aug, 2021 | 08:54h | UTCEditorials:
Author interview: USPSTF Recommendation: Screening for Prediabetes and Type 2 Diabetes – JAMA
Evidence report: Screening for Prediabetes and Type 2 Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
JAMA Patient Page: Screening for Prediabetes and Type 2 Diabetes
RCT: Catheter-based adrenal ablation remits primary aldosteronism.
25 Aug, 2021 | 08:52h | UTCCatheter-Based Adrenal Ablation Remits Primary Aldosteronism: A Randomized Medication-Controlled Trial – Circulation (free for a limited period)
Commentary on Twitter
#ResearchLetter: RCT data show catheter-based adrenal ablation effectively ⬇️ BP in primary aldosteronism comparable to spironolactone – A potential therapy for patients unable to tolerate medications? https://t.co/ImSAdnVtxE #AHAJournals pic.twitter.com/WSJjFpzKPo
— Circulation (@CircAHA) August 21, 2021
RCT: No effect of Vitamin D supplementation on kidney function in adults with prediabetes.
25 Aug, 2021 | 08:41h | UTCEffect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary on Twitter
Low circulating 25-hydroxyvitamin D concentration has been suggested as a risk factor for both type 2 diabetes and kidney disease. This study found that in persons with prediabetes, vitamin D supplementation did not affect progression of KDIGO risk scores https://t.co/e1EmP403TD pic.twitter.com/yEQjrvZr7A
— CJASN (@CJASN) August 24, 2021
Things we do for no reason: routinely holding metformin in the hospital.
25 Aug, 2021 | 08:43h | UTC
RCT: SGLT2 inhibition reduces the risk of hyperkalemia in patients with diabetes and chronic kidney disease.
24 Aug, 2021 | 08:57h | UTCEffects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial – European Heart Journal (link to abstract – $ for full-text)
Commentary on Twitter
SGLT2 inhibition reduces the risk of serious hyperkalemia in people with diabetic kidney disease, which may enable greater use of RAAS inhibitors in CKD and/or heart failure
New CREDENCE data presented this week at #ESCCongress, now in @ESC_Journals:https://t.co/OEqnXTdBDi pic.twitter.com/zsanEFZVCy
— Brendon Neuen (@brendonneuen) August 23, 2021
ACOG Guideline: Osteoporosis prevention, screening, and diagnosis.
22 Aug, 2021 | 23:08h | UTC
M-A: GLP-1 receptor agonists reduce major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes.
22 Aug, 2021 | 22:50h | UTCCardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
M-A: The role of SGLT2 inhibitors in heart failure.
22 Aug, 2021 | 22:46h | UTCRelated:
ESC Position Paper: Cardiac, renal, and metabolic effects of SGLT2 inhibitors.
Summary: SGLT2 inhibitors and GLP-1 receptor agonists established and emerging indications.
Review: Prevention of Microvascular Complications of Diabetes.
18 Aug, 2021 | 08:34h | UTC
Cohort study: cardiovascular and kidney outcomes across the glycemic spectrum – Prediabetes and T2D were independently associated atherosclerotic cardiovascular disease; substantial gradient of risk was observed across HbA1c levels.
18 Aug, 2021 | 08:36h | UTCCommentary: Cardiovascular and Kidney Outcomes in Diabetes and Prediabetes – American College of Cardiology
Type 2 diabetes: more than one type of diet can help people achieve remission.
18 Aug, 2021 | 08:32h | UTCType 2 diabetes: more than one type of diet can help people achieve remission – The Conversation
Original article: Dietary strategies for remission of type 2 diabetes: A narrative review – Journal of Human Nutrition and Dietetics (link to abstract – $ for full-text)
RCT: Once-weekly tirzepatide vs. once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes.
17 Aug, 2021 | 08:50h | UTCOnce-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Related:
Study: Metabolism peaks much earlier and starts to decline later than you might think.
16 Aug, 2021 | 00:44h | UTCMetabolism peaks much earlier and starts to decline later than you might think – News Medical
Original study: Daily energy expenditure through the human life course – Science (link to abstract – $ for full-text)
Commentary on Twitter
Excellent paper by @HermanPontzer et al showing that TDEE does not change during adulthood (20-60y).
Middle age spread is likely not caused by a slowing of the metabolism (& decrease in energy expenditure) but rather by changes in energy intake.
https://t.co/327DCKjOru— Christoph Höchsmann (@CHoechsmann) August 14, 2021
Changes in food purchases after the Chilean policies on food labelling, marketing, and sales in schools: a before and after study.
16 Aug, 2021 | 00:39h | UTCCommentary: Sugary drink consumption plunges in Chile after new food law – University of North Carolina at Chapel Hill
Related:
UK National Food Strategy: Tax sugar and salt and prescribe veg, report says.
Fiscal policies for diet and the prevention of noncommunicable diseases – World Health Organization
The Lancet taskforce on NCDs and economics (free series and commentaries)
To improve global health, tax the things that are killing us – Financial Times (policies, articles and commentaries)
Reducing cardiovascular disease burden through targeted dietary policies (study and commentaries)
Fiscal policies for the prevention of diseases (study and commentary)
U.S. Study: Ultraprocessed Foods Now Comprise 2/3 of Calories in Children and Teen Diets.
16 Aug, 2021 | 00:41h | UTCTrends in Consumption of Ultraprocessed Foods Among US Youths Aged 2-19 Years, 1999-2018 – JAMA (free for a limited period)
Editorial: Intake of Ultraprocessed Foods Among US Youths: Health Concerns and Opportunities for Research and Policy (free for a limited period)
News release: Ultraprocessed Foods Now Comprise 2/3 of Calories in Children and Teen Diets – Tufts University
Commentaries:
If You Think Kids Are Eating Mostly Junk Food, A New Study Finds You’re Right – NPR
Related:
Cohort Study: Association Between Consumption of Ultra-processed Foods and All Cause Mortality
Research: Consumption of Ultra-Processed Foods and Cancer Risk
Randomized Trial: Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain
Ultra-Processed Foods and Incident Cardiovascular Disease in the Framingham Offspring Study
Commentary on Twitter (thread – click for more)
https://twitter.com/Dmozaffarian/status/1425155359849730052
Secondary analysis of RCT finds Dapagliflozin is safe for patients with stage 4 chronic kidney disease.
10 Aug, 2021 | 08:51h | UTCCommentaries:
No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD – HealthDay
Mammographic features are associated with cardiometabolic disease risk and mortality.
6 Aug, 2021 | 09:04h | UTC
Ketogenic Diets and Chronic Disease: Weighing the Benefits Against the Risks – “Given often-temporary improvements, unfavorable effects on dietary intake, and inadequate data demonstrating long-term safety, for most individuals, the risks of ketogenic diets may outweigh the benefits.”
4 Aug, 2021 | 08:53h | UTC
M-A: Association between adiposity and cardiovascular outcomes.
3 Aug, 2021 | 02:11h | UTC
Commentary on Twitter
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. Discover more in EHJ! https://t.co/HOgWqBkemn#CVD #CAD #stroke #adiposity #metaanalysis #cardiotwitter @escardio @ESC_Journals pic.twitter.com/UmiOO3EbnU
— EHJ Editor-in-Chief (@ehj_ed) August 2, 2021
Serious complications from youth-onset type 2 diabetes arise by young adulthood.
30 Jul, 2021 | 11:47h | UTCCommentary: Serious complications from youth-onset type 2 diabetes arise by young adulthood – NIH News Release
Original study: Long-Term Complications in Youth-Onset Type 2 Diabetes – New England Journal of Medicine
Commentary on Twitter
High rates of complications in youth onset T2 diabetes.
Complication occurred in 60% after 13 yearsRisk factors for development of complications:
Ethnic minority
Hyperglycaemia
Hypertension
DyslipidaemiaImportance of risk factor controlhttps://t.co/UcUnuLv0PC pic.twitter.com/TfLEASSQnQ
— Prof Kamlesh Khunti (@kamleshkhunti) July 29, 2021
2021 ACC expert consensus decision pathway for cardiovascular risk reduction in patients with persistent hypertriglyceridemia.
29 Jul, 2021 | 11:15h | UTCKey points: ACC Consensus on ASCVD Risk Reduction in Hypertriglyceridemia – American College of Cardiology
Commentary on Twitter
The ACC Expert Consensus Decision Pathway highlights 9️⃣ key points to remember on the management of atherosclerotic #CVD risk reduction in patients with persistent hypertriglyceridemia. Learn more here: https://t.co/zTx4gsIQS2 #ASCVD #cvCAD #Diabetes @virani_md @PamelaBMorris pic.twitter.com/Zjo4wmeZVj
— American College of Cardiology (@ACCinTouch) July 28, 2021
ESC Position Paper: Cardiac, renal, and metabolic effects of SGLT2 inhibitors.
29 Jul, 2021 | 11:13h | UTC
Review: Lipoprotein(a) and Cardiovascular Diseases.
29 Jul, 2021 | 10:56h | UTCLipoprotein(a) and Cardiovascular Diseases – JAMA (free for a limited period)